AstraZeneca plc (NYSE:AZN) announced an agreement with Europe's Inclusive Vaccines Alliance (IVA) to supply 400 million doses of its coronavirus vaccines by the end of the year.
AZN recently signed deals in the U.K., U.S. and with CEPI and Gavi, the Vaccine Alliance, to supply 700 million doses, in addition to a deal with the Serum Institute of India to supply IB doses to low- and middle-income countries.
Manufacturing costs will be offset by government funding. A Phase 2/3 trial in the U.K. launched last month.
AZN's 2020 financial guidance remains unchanged.
Monday morning brought word that Catalent's Biologics unit inks an agreement with AstraZeneca to provide vial filling and packaging services at its facility in Anagni, Italy and prepare for large-scale commercial supply of its COVID-19 vaccine candidate AZD1222.
Catalent will prepare the facility for around-the-clock manufacturing schedules aimed at supplying "hundreds of millions" of doses from August of this year to, potentially, March 2022 if the vaccine is approved by regulators.
Financial terms were not disclosed.
AZN shares gained 48 cents to $51.93.
Related Stories
